A study carried out in Argentina and published in the journal EClinical Medicin of The Lancet publishing group provides evidence of the significant antiviral activity of ivermectin against the Chinese Communist Party (CCP) Virus, or COVID-19.
Although the study was conducted last year, the publication in the renowned scientific journal was on June 17, which caused the research and its encouraging results to be widely disseminated.
This study aimed to evaluate the antiviral effect of ivermectin (IVM) on the viral load of respiratory secretions and its relationship with the plasma concentrations of the antiparasitic medication.
The test was performed on 45 randomly selected participants from May 18 to September 9, 2020.
“Our study contributes evidence of the antiviral activity of iVM against SARS-CoV-2 in patients with COVID-19 through a randomized, controlled, outcome-assessor blinded clinical trial with innovative analyses,” write the researchers.
“The use of an untreated control group highlights the need for controlled trials and on the viral load dynamics in the natural history of COVID-19,” they added.
The authors conclude that: “A concentration dependent antiviral effect of iVM in COVID-19 was identified, with significant reductions in SARS-CoV-2 viral load in respiratory secretions among patients achieving high systemic ivermectin concentration compared to untreated controls.”
“These results, that did not show toxicity related to the use of high dose ivermectin, provide evidence of the antiviral effect and support the design of trials to investigate the clinical implications of our findings. Further exploration of the factors involved in the oral bioavailability of ivermectin are also warranted,” said the authors of the study, including Alejandro Krolewieckia, Marina Travaciod, Luis Álvarez, Marcelo Golembac, Inés Baeck, and Georgina Cardama.
They also indicated that administration of ivermectin at a dose of 0.6 milligrams per kilogram of body weight results in the most rapid and profound elimination of the virus when treatment is initiated in the early stages of infection (up to 5 days from symptom onset).
The potential role of ivermectin against the CCP Virus was first reported in April 2020 when Australian scientists published very encouraging results.
29.5% reduction in fatalities
On June 9, the Ministry of Health of the Argentine province of La Pampa reported that a study of 2,000 patients treated with IVM reduced by 39% the use of intensive therapy and by 29.5% the number of fatal cases.
From a preliminary analysis of the clinical evolution of 2,000 people who entered the ivermectin program from January to May 10 of this year, and of 12,600 patients who were diagnosed during the same period but who did not participate in this monitored intervention, it was found that, in those over 40 years of age, the frequency of hospitalization in intensive care was nearly 40% lower in those who received ivermectin.
Likewise, the development of severe forms of the disease (defined as admission to intensive care or death of the patients) was 35% less frequent in patients treated with ivermectin than in those who did not participate in the program.
According to La Pampa’s Minister of Health, Mario Kohan, “we believe that these data are encouraging and invite us to continue on the path initiated in January”.
Although its use is not approved by the regulatory agency in Argentina (Anmat), these results plus those of other similar studies may encourage support for further research.
Health authorities in Peru, Bolivia and parts of Brazil have also endorsed the use of iVM.
More about Ivermectin
Ivermectin is a product best known for its veterinary use. It was discovered by Japanese scientist Satoshi Omura, who won the Nobel Prize precisely for this finding.
First introduced as a commercial product for animals in 1981, IVM proved useful against a wide range of parasites, such as lungworms, mites, lice, intestinal worms, and ticks.
Next, Australian researchers found that IVM exerts potent anti-viral effects against two viruses that cause life-threatening human diseases, human immunodeficiency virus-1 (HIV-1) and dengue virus (DENV).
Ivermectin has also been found to limit infection by other viral pathogens, such as Venezuelan equine encephalitis virus and influenza virus.
Because of these reports, other researchers committed to the actual welfare of people decided to test the activity of IVM against the CCP Virus.
While this drug has been shown in several investigations to be effective against the HCCP virus, it has suffered major smear campaigns and censure, as has hydroxychloroquine.
However, independent research is increasingly turning in their favor and showing these drugs as plausible alternatives to combat the virus.